The steroid drug, deflazacort, which treats Duchenne muscular dystrophy, has been approved overseas for years and is sold as a generic.
Families here have been importing a year's worth for around $1,200.
But Marathon Pharmaceuticals finally got it FDA-approved Thursday under an "orphan drug" status, which covers drugs that treat rare diseases. (Duchenne affects about 15,000 people in the US.)
Under that status, Marathon has exclusive rights to sell deflazacort in the US for seven years. They are using that monopoly status to charge $89,000 a year for the drug😱
To read full article - https://goo.gl/qpQZHz